IECM
CRL icon

Intrinsic Edge Capital Management’s Charles River Laboratories CRL Stock Holding History

Intrinsic Edge Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$1.99M – 122
2025
Q4 		$1.99M Buy
+10,000
New +$1.81M 0.36% 65
2023
Q3 		– Sell
-20,000
Closed -$4.21M – 143
2023
Q2 		$4.21M Buy
+20,000
New +$3.98M 0.3% 103

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Intrinsic Edge Capital Management's CRL Position: Q1 2026 in Review

Intrinsic Edge Capital Management sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 10,000 shares — an estimated $1.99M sold.

Intrinsic Edge Capital Management first reported a position in CRL in Q2 2023 and held it in 2 quarters. The position peaked at $4.21M in Q2 2023. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Intrinsic Edge Capital Management reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 10,000 Charles River Laboratories shares in Q1 2026, an estimated $1.99M.
  • Intrinsic Edge Capital Management first reported a position in Charles River Laboratories in Q2 2023 and held it in 2 quarters.
  • Intrinsic Edge Capital Management's Charles River Laboratories position peaked at $4.21M in Q2 2023.
  • 560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Intrinsic Edge Capital Management's 13F filing for Q1 2026, filed 18 May 2026.